ER+ breast cancer patients with high FGFR1 mRNA expression at baseline show resistance to a CDK4/6 inhibitor + letrozole and had a poor prognosis in the MONALEESA-2 study [14]. This evidence concerns the gene FGFR1 and breast carcinoma.